Clinical medicine. Oncology最新文献

{"title":"Multidisciplinary approach in managing orbital tumors in ibadan, Nigeria.","authors":"T S Oluleye, A O Fasola, O Komolafe","doi":"10.4137/cmo.s757","DOIUrl":"https://doi.org/10.4137/cmo.s757","url":null,"abstract":"","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"2 ","pages":"385-7"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/cmo.s757","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30120479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Octreotide in Palliative Treatment of Hepatic Metastases: Is it Effective for Clinical Stabilization?","authors":"Kiki Pistevou-Gompaki, Nikos Eleftheriadis, Damianos Eleftheriadis, Christos Papaloukas, Apostolos Hatzitolios","doi":"10.4137/cmo.s409","DOIUrl":"https://doi.org/10.4137/cmo.s409","url":null,"abstract":"","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"2 ","pages":"401-3"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/cmo.s409","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30120482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid carcinoma with bone metastases: a prognostic factor study.","authors":"Karl Wu,&nbsp;Shen-Mou Hou,&nbsp;Tien-Shang Huang,&nbsp;Rong-Sen Yang","doi":"10.4137/cmo.s333","DOIUrl":"https://doi.org/10.4137/cmo.s333","url":null,"abstract":"<p><strong>Objective: </strong>Occult clinical presentations usually hinder the early detection and management of patients with bone metastases from thyroid carcinoma. We retrospectively investigated the clinical outcomes of such patients from 1993 to 2004 and analyzed the prognostic parameters.</p><p><strong>Design: </strong>The basic demographic data and manifestations of 44 patients who had thyroid carcinoma with bone metastases were reviewed. We studied the gender, age, locations of metastases, histological types, treatment methods, hypercalcemic episodes and results of treatments. We used Kaplan-Meier survival analysis and log-rank tests to access the statistical significance.</p><p><strong>Main outcome: </strong>The incidence of bone metastasis from thyroid carcinomas in this series was 5.0%. Twenty patients (45.4%) had follicular, 16 (36.3%) had papillary, 3 (6.8%) had anaplastic, 3 (6.8%) had medullary, and 2 (4.5%) had Hurthel cell carcinomas. Twelve patients had hypercalcemic episodes, ranging from 2.6 to 2.9 mmolL(-1) (mean ± SD: 2.68 ± 0.15 mmolL(-1)). Survival time after bone metastases ranged from 2 months to 8 years (mean ± SD: 5.3 ± 1.3 years). The 5-year survival rate was 79.4% and the 10-year survival rate was 52.9%. Regarding the histological cancer type, patients with papillary and follicular cancers survived significantly longer than those with anaplastic and medullary cancers (p < 0.05). In addition, the patients presenting with hypercalcemia had the worst survival (p < 0.05).</p><p><strong>Conclusions: </strong>Thyroid carcinoma can present with bone metastases in its early stage. We found that both tumor type and hypercalcemia were significant prognostic factors for survival time.</p>","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"2 ","pages":"129-34"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/cmo.s333","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30121207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological Markers Predictive of Invasive Recurrence in DCIS.","authors":"Sharon Nofech-Mozes,&nbsp;Jacqueline Spayne,&nbsp;Eileen Rakovitch,&nbsp;Harriette J Kahn,&nbsp;Arun Seth,&nbsp;Jean-Phillippe Pignol,&nbsp;Lavina Lickley,&nbsp;Lawrence Paszat,&nbsp;Wedad Hanna","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>DCIS is a heterogeneous group of non-invasive cancers of the breast characterized by various degrees of differentiation and unpredictable propensity for transformation into invasive carcinoma. We examined the expression and prognostic value of 9 biological markers with a potential role in tumor progression in 133 patients with pure DCIS treated with breast conserving surgery alone, between 1982-2000. Histology was reviewed and immunohistochemical staining was performed. Pearson correlation coefficient was used to determine the associations between markers and histopathological features. Univariate and multivariate analysis examined associations between time to recurrence and clinicopathologic features and biological markers.Median age at diagnosis was 55 years (25-85). With a median follow up of 8.91 years, 41/133 patients recurred (21 as invasive recurrence). In this cohort 13.5% had low, 43% intermediate and 42% high nuclear grade. Comedo necrosis was found in 65% of cases. Expression of ER (62.4%), PR (55.6%), HER2/neu (31.6%), MIB1 (39.8%), p53 (22.6%), p21 (39.8%), Cyclin D1 (95.5%) calgranulin (20.5%), psoriasin (12%), was found in DCIS. HER2/neu was overexpressed in 45% that recurred as DCIS and 42.9% that recurred as invasive cancer, and only in 26.1% in cases that never recurred. On univariate analysis, HER2/neu overexpression was the only marker associated with an increased risk for any recurrence (p = 0.044). The hazard ratio for recurrence for HER2/neu positive DCIS was 1.927 (confidence interval 1.016-3.653) compared to HER2 negative DCIS. On multivariate analysis, HER2/neu overexpression remained the only independent variable significantly associated with any recurrence (p = 0.014) and with invasive recurrence (p = 0.044).This data suggest that HER2/neu testing may become an important parameter in the management of DCIS and the treatment of cases with positive HER2/neu status could be modified accordingly, similar to the current approach for HER2/neu positive invasive disease.</p>","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"2 ","pages":"7-18"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29974333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical fibroxanthoma.","authors":"Akio Sakamoto","doi":"10.4137/cmo.s506","DOIUrl":"10.4137/cmo.s506","url":null,"abstract":"<p><p>Atypical fibroxanthoma (AFX) is a nodular dermal ulcerative lesion with a favorable prognosis. AFX most commonly occurs on sun-exposed skin in elderly individuals. AFX is characterized by its association with ultraviolet radiation, not only from a clinical aspect, but also from a molecular aspect. Making a diagnosis of AFX is challenging, and it is important to differentiate it from squamous cell carcinoma and malignant melanoma. Histological features and combined immunohistochemical markers are necessary for a definitive diagnosis (i.e., an absence of immunostaining for cytokeratins, S100 and HMB45 in AFX is helpful for excluding both squamous cell carcinoma and malignant melanoma). AFX, as well as MFH (malignant fibrous histiocytoma), is a fibrohistiocytic lesion with myofibroblastic differentiation. AFX is considered to be a different lesion from MFH. AFX and MFH might share the same pathway which determines their morphology. However, they may have different pathways in development which determine their biological behavior.</p>","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"2 ","pages":"117-27"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29975344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of clinicopathological features and molecular markers in british and nigerian women with breast cancer.","authors":"Isaac D Gukas,&nbsp;Anne C Girling,&nbsp;Barnabas M Mandong,&nbsp;Wendy Prime,&nbsp;Barbara A Jennings,&nbsp;Samuel J Leinster","doi":"10.4137/cmo.s474","DOIUrl":"https://doi.org/10.4137/cmo.s474","url":null,"abstract":"<p><strong>Background: </strong>Some studies have suggested that breast cancer in black women is more aggressive than in white women. This study's aim was to look for evidence of differences in tumour biology between the two cohorts.</p><p><strong>Methods: </strong>This study compared the stage, grade and pathological expression of five immunohistochemical markers (oestrogen receptor [ER], progesterone receptor [PR], ERBB2, P53 and cyclin D1 [CCND1]) in tumour biopsies from age-matched cohorts of patients from Nigeria and England. Sixty-eight suitable samples from Nigerian (n = 34) and British (n = 34) breast cancer patients were retrieved from histology tissue banks.</p><p><strong>Results: </strong>There were significant differences between the two cohorts in the expression of ER and CCND1; and stark differences in the clinical stage at presentation. But no significant differences were observed for tumour grade.</p><p><strong>Conclusion: </strong>There was a significantly, low ER expression in the Nigerian cases which also predicts a poor response to hormonal therapy as well as a poorer prognosis. Differences in clinical stage at presentation will most likely influence prognosis between Nigerian and British women with breast cancer.</p>","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"2 ","pages":"347-51"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/cmo.s474","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30119378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 'Pokemon' (ZBTB7) Gene: No Evidence of Association with Sporadic Breast Cancer.","authors":"Antonio Salas,&nbsp;Ana Vega,&nbsp;Roger L Milne,&nbsp;Manuel García-Magariños,&nbsp;Alvaro Ruibal,&nbsp;Javier Benítez,&nbsp;Angel Carracedo","doi":"10.4137/cmo.s569","DOIUrl":"https://doi.org/10.4137/cmo.s569","url":null,"abstract":"<p><p>It has been proposed that the excess of familiar risk associated with breast cancer could be explained by the cumulative effect of multiple weakly predisposing alleles. The transcriptional repressor FBI1, also known as Pokemon, has recently been identified as a critical factor in oncogenesis. This protein is encoded by the ZBTB7 gene. Here we aimed to determine whether polymorphisms in ZBTB7 are associated with breast cancer risk in a sample of cases and controls collected in hospitals from North and Central Spanish patients. We genotyped 15 SNPs in ZBTB7, including the flanking regions, with an average coverage of 1 SNP/2.4 Kb, in 360 sporadic breast cancer cases and 402 controls. Comparison of allele, genotype and haplotype frequencies between cases and controls did not reveal associations using Pearson's chi-square test and a permutation procedure to correct for multiple test. In this, the first study of the ZBTB7 gene in relation to, sporadic breast cancer, we found no evidence of an association.</p>","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"2 ","pages":"357-62"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/cmo.s569","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30119381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The presence of precursors of benign pre-B lymphoblasts (hematogones) in the bone marrow of a paediatric patient with cytomegalovirus infection.","authors":"F Moreno-Madrid,&nbsp;J Uberos,&nbsp;M Díaz-Molina,&nbsp;A Ramírez-Arredondo,&nbsp;P Jiménez-Gámiz,&nbsp;A Molina-Carballo","doi":"10.4137/cmo.s751","DOIUrl":"https://doi.org/10.4137/cmo.s751","url":null,"abstract":"<p><p>Hematogones are normal B-lymphoid precursors that multiply in the bone marrow of small children and of adults with ferropenic anaemia, neuroblastoma or idiopathic thrombocytopenic purpura. They are not normally found in peripheral blood, and the immunophenotype is virtually indistinguishable from that of B lymphoblasts. We discuss the case of a 3-month infant with an active cytomegalovirus infection, with hepatitis and pancytopenia associated with 13% hematogones in the bone marrow.</p>","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"2 ","pages":"437-9"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/cmo.s751","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30119763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicentric Adenocarcinomas in a Long-Segment of Barrett's Esophagus.","authors":"Stefan Hartl,&nbsp;Joerg-Ruediger Siewert,&nbsp;Joerg Theisen","doi":"10.4137/cmo.s287","DOIUrl":"https://doi.org/10.4137/cmo.s287","url":null,"abstract":"<p><p>This report describes a complicated course of a 58-year-old patient with multicentric Barrett's carcinoma within a long-segment of Barrett metaplasia. After abdominal-thoracic resection of the cancer, with incomplete removal of the long-segment metaplastic lesion, invasive carcinoma was diagnosed in the remnant Barrett's segment. Endoscopic mucosal resection was done, but Barrett's mucosa was left in situ again. Recurrent tumor growth was diagnosed only few months later. Finally, transthoracic complete resection on the remnant Barrett's segment was performed. Thus, our case demonstrates impressively the appearance of multicentric adenocarcinomas in Barrett's esophagus and underlines the necessity of resection of the complete Barrett mucosa.</p>","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"2 ","pages":"441-3"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/cmo.s287","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30119764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-operative Concomitant Radio-chemotherapy in Bulky Carcinoma of the Cervix: A Single Institution Study.","authors":"Anne de la Rochefordiere,&nbsp;Youlia Kirova,&nbsp;Severine Alran,&nbsp;Corine Plancher,&nbsp;Virginie Fourchotte,&nbsp;Philippe Beuzeboc,&nbsp;Vincent de Margerie,&nbsp;Peter Petrow,&nbsp;Xavier Sastre-Garau,&nbsp;Vincent Servois,&nbsp;Suzy Scholl,&nbsp;Paul Cottu,&nbsp;Laurent Mignot,&nbsp;Patricia de Cremoux,&nbsp;Remy Salmon","doi":"10.4137/cmo.s489","DOIUrl":"https://doi.org/10.4137/cmo.s489","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the treatment results of patients (pts) with FIGO stage IB2, IIA, IIB cervical carcinoma (CC) treated with pre-operative radio-chemotherapy, followed by extended radical hysterectomy.</p><p><strong>Methods: </strong>Retrospective study of 148 women treated to the Institut Curie for operable FIGO Stage IB2 to IIB, biopsy proved CC. Among them, 70 pts, median age 46 years, were treated using the same regimen associating primary radio-cisplatinum based chemotherapy, intracavitary LDR brachytherapy, followed by extended radical hysterectomy. Kaplan-Meier estimates were used to draw survival curves. Comparisons of survival distribution were assessed by the log-rank test.</p><p><strong>Results: </strong>Complete histological local-regional response was obtained in 56% of the pts (n = 39). Residual macroscopic or microscopic disease in the cervix was observed in 28 pts (40%). All but one had in-situ microscopic residual CC. Lateral residual disease in the parametria was also present in 9 pts, all with residual CC. Pelvic lymph nodes were free from microscopic disease in 56 pts (80%). Eight of 55 (11%) radiological N0 patients had microscopic nodal involvement, as compared to 6/15 (40%) radiological N1 (p = 0.03). Seventeen pts (25%) had residual cervix disease but negative nodes. After median follow-up of 40 months (range, 8-141), 38/70 patients (54.1%) are still alive and free of disease, 6 (8.6%) alive with disease, and 11 (15.8%) patients were lost for follow-up but free of disease.</p><p><strong>In conclusion: </strong>The treatment of locally advanced CC needs a new multidisciplinary diagnostic and treatment approach using new therapeutic arms to improve the survival and treatment tolerance among women presenting this disease.</p>","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"2 ","pages":"227-36"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/cmo.s489","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30119985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}